Tous Actualités
Suivre
Abonner Intercell AG

Intercell AG

euro adhoc: Intercell AG
Joint Ventures/Cooperation/Collaboration
Intercell signs license agreement with newly founded Pelias AG

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
09.12.2005
Vienna (Austria), December 9, 2005 - Intercell AG today announced the
signing of an exclusive license agreement with Pelias Biomedical
Development AG (Pelias) in the field of hospital-acquired infections.
The vaccine company Pelias has been founded recently as a new biotech
startup by Intercell and partners including Chiron, Parteurop,
BioAlliance and Kapital&Wert Group.
The license agreement will give Pelias access to certain antigens,
targeting important pathogens in hospital infections, which have been
identified by Intercells’ proprietary Antigen Identification Program
(AIP®). Together with the license, certain early stage preclinical
development assets in the license field will be transferred from
Intercell to Pelias. Intercell will receive an up-front consideration
and royalty payments on future product sales. In addition, Intercell
holds a major stake of shares in Pelias.
Through this license, together with a clinical stage Pseudomonas
vaccine candidate, which was licensed from Chiron, Pelias will be
positioned as an emerging specialist in vaccines and antibody-based
therapies for the prevention and treatment of hospital-acquired
infections. Pelias has received initial funding from Intercell and
Kapital&Wert Group and is seeking further venture capital funding.
Werner Lanthaler, Intercell’s CFO, explains the strategy behind the
Pelias deal: "Our Antigen Identification technology provides us with
a lot more vaccine targets than we can support in our development
pipeline - some of them are partnered with major vaccine companies
like Merck&Co., Inc. and sanofi pasteur. The Pelias deal provides us
with the same upside in terms of future royalties, but combined with
an equity stake in an attractive early stage company, that is ideally
positioned to raise external funding from the venture markets. We
think this model is an efficient way to leverage the value of our
vaccine technologies without increasing our own R&D spend."
This communication expressly or implicitly contains certain
forward-looking statements concerning Intercell AG and its business.
Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Intercell AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Intercell AG is providing this communication as of this date and does
not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.
end of announcement                               euro adhoc 09.12.2005 08:55:00

Further inquiry note:

Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market

Plus de actualités: Intercell AG
Plus de actualités: Intercell AG